Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Phase 1

3(75.0%)

Phase 4

1(25.0%)

4Total

Phase 1(3)

Phase 4(1)

Loading network data...

Showing 4 of 4 trials

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers

Role: collaborator

Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

Role: collaborator

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Role: collaborator

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Role: collaborator

All 4 trials loaded